Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 31 Neoplasms 8 Endometrial Neoplasms 6 Neoplasm Metastasis 5 Brain Neoplasms 5 Triple Negative Breast Neoplasms 4 Prostatic Neoplasms 4 Ovarian Neoplasms 4 Head and Neck Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 3 Meningioma 3 Glioblastoma 3 Sarcoma 2 Pancreatic Neoplasms 2 Oligodendroglioma 2 Lymphoma, Non-Hodgkin 2 Carcinoma, Non-Small-Cell Lung 2 Urologic Neoplasms 1 Thyroid Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Spinal Cord Neoplasms 1 Small Cell Lung Carcinoma 1 Sarcoma, Ewing 1 Retinoblastoma 1 Recurrence 1 Pathologic Complete Response 1 Osteosarcoma 1 Neoplasms, Squamous Cell 1 Neoplasm, Residual 1 Multiple Myeloma 1

Interventions

Cyclophosphamide 17 Trastuzumab 16 Paclitaxel 15 Doxorubicin 11 Docetaxel 10 Radiotherapy 9 Carboplatin 9 Capecitabine 9 Bevacizumab 8 Lapatinib 7 Taxes 6 Tamoxifen 6 Gemcitabine 5 Filgrastim 5 Chemotherapy, Adjuvant 5 sargramostim 4 Sorafenib 4 Radiation 4 Neoadjuvant Therapy 4 Granulocyte-Macrophage Colony-Stimulating Factor 4 Vinorelbine 3 Thiotepa 3 Peripheral Blood Stem Cell Transplantation 3 Melphalan 3 Irinotecan 3 Immunohistochemistry 3 Granulocyte Colony-Stimulating Factor 3 Erlotinib Hydrochloride 3 Anastrozole 3 Albumin-Bound Paclitaxel 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Breast Neoplasms, Male × abemaciclib × Clear all

NCT05501704 2026-04-30

ETHAN - ET for Male BC

Dana-Farber Cancer Institute

Phase 2 Recruiting

Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon ⚡